Q-omics provides the consensus-scored MPP2 profile across patient tissues and cancer cell-line models. MPP2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MPP2 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, MPP2 protein abundance shows 23,244 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, KIRC, and GBM as cancer lineages where MPP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MPP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MPP2 survival associations across molecular data types. MPP2 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (8) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MPP2 RNA expression–survival associations across cancer types. High MPP2 expression shows unfavorable associations in ACC, KIRC, MESO, COAD, KICH and LUSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MPP2 RNA expression.
This table summarizes MPP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 9. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MPP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MPP2 shows lower tumor expression in KIRC, COAD, THCA, KICH, BLCA and READ. The KIRC box plot shows higher MPP2 RNA expression in normal versus tumor tissue (log2 FC = −1.384, t-test p < 0.001).
This table shows molecular features associated with MPP2 in patient tissues and cancer cell lines. In patient samples, MPP2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, MPP2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and SOFT_TISSUE.
